New findings showcase the potential of in vivo CAR-M technology as an effective, off-the-shelf treatment for hepatocellular carcinoma (HCC) Pre-clinical results showed that the novel in vivo anti-GPC3 ...
Recent advancements in cancer immunotherapy have highlighted glypican-3 (GPC3) as a prominent target for treating hepatocellular carcinoma (HCC). However, approximately 10% to 30% of HCC patients ...
EMERYVILLE, Calif., and LOS ANGELES, May 31, 2022 - Eureka Therapeutics Inc., a clinical-stage biotechnology company developing novel T cell therapies to treat solid tumors, and City of Hope, one of ...
-MT-303 programs immune cells directly in patients; the first time an in vivo CAR has been evaluated clinically in HCC- MT-303 is a first-in-class Glypican-3 (GPC3) targeting CAR encoded from mRNA and ...
CAMBRIDGE, Mass., July 31, 2024 /PRNewswire/ -- Myeloid Therapeutics, Inc. ("Myeloid"), a clinical-stage immunology company advancing RNA therapeutics to conquer cancer, has dosed the first patient ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback